Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun;18(6):623-6.

Association between mutations in gyrA and parC genes of Acinetobacter baumannii clinical isolates and ciprofloxacin resistance

Abdollah Ardebili  1 , Abdolaziz Rastegar Lari  2 , Maryam Beheshti  3 , Elnaz Rastegar Lari  4
Affiliations

Association between mutations in gyrA and parC genes of Acinetobacter baumannii clinical isolates and ciprofloxacin resistance

Abdollah Ardebili et al. Iran J Basic Med Sci. 2015 Jun.

Abstract

Objectives: We investigated the contribution of gyrA and parC mutational mechanism in decreased ciprofloxacin susceptibility of Acinetobacter baumannii isolated from burn wound infections.

Materials and methods: Ciprofloxacin susceptibility of 50 A. baumannii isolates was evaluated by disk diffusion and agar dilution methods. PCR and sequencing were performed for detection of mutation in gyrA and parC genes.

Results: The 44 and 4 isolates of A. baumannii exhibited full and intermediate-resistant to ciprofloxacin, respectively. Overall, the 42 isolates with double mutations of gyrA and parC genes showed a higher level of ciprofloxacin resistance than the 3 isolates with single mutations of gyrA or parC.

Conclusion: Simultaneous mutations in gyrA and parC genes are expected to play a major role in high-level fluoroquinolone resistance in A. baumannii; albeit a single mutation in DNA topoisomerase IV could occasionally be associated with intermediate-resistance to these antimicrobials.

Keywords: Acinetobacter baumannii; Burn; Ciprofloxacin resistance; gyrA; parC.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

No declarations were made by the authors of this paper.

Figures

Figure 1
Figure 1
PCR amplification of the QRDRs of the gyrA (A) and parC (B) genes in Acinetobacter baumannii isolates. Lanes: 1- 7, PCR products of the corresponding genes; M, 100 bp Plus DNA Ladder
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1–12. - PubMed
    1. Towner KJ, Levi K, Vlassiadi M. Genetic diversity of carbapenem-resistant isolates of Acinetobacter baumannii in Europe. Clin Microbiol Infect. 2008;14:161–167. - PubMed
    1. Ardebili A, Talebi M, Azimi L, Lari AR. Effect of efflux pump inhibitor CCCP on the MIC of ciprofloxacin in Acinetobacter baumannii clinical isolates. Jundishapur J Microbiol. 2014;7 doi:10.5812/jjm.8691. - PMC - PubMed
    1. Valentine SC, Contreras D, Tan S, Real LJ, Chu S, Xu HH. Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California. J Clin Microbiol. 2008;46:2499–2507. - PMC - PubMed
    1. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis. 2005;41:120–126. - PubMed

LinkOut - more resources